Monoclonal antibodies in cancer immunotherapy

被引：139

作者：

Kimiz-Gebologlu, Ilgin ^{[1
]}

Gulce-Iz, Sultan ^{[1
,2
,3
]}

Biray-Avci, Cigir ^{[4
]}

机构：

[1] Ege Univ, Inst Nat & Appl Sci, Bioengn Grad Programme, Izmir, Turkey

[2] Ege Univ, Dept Bioengn, Fac Engn, Izmir, Turkey

[3] Ege Univ, Biomed Technol Grad Programme, Inst Nat & Appl Sci, Izmir, Turkey

[4] Ege Univ, Med Sch, Dept Med Biol, Izmir, Turkey

来源：

MOLECULAR BIOLOGY REPORTS | 2018年 / 45卷 / 06期

关键词：

Immunotherapy; Monoclonal antibody; Cancer; Treatment; THERAPEUTIC ANTIBODIES; CYTOTOXICITY ACTIVITY;

D O I：

10.1007/s11033-018-4427-x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Nowadays, in cancer treatments, immunotherapy which can be classified as a cancer type specific therapy is more popular than non-specific therapy methods such as surgery, radiotherapy and chemotherapy. The main aim of immunotherapy is to enable patients' immune system to target cancer cells and destroy them. The mainly used treatment methods in cancer immunotherapy are cancer vaccines, adoptive cell therapy, cytokines and monoclonal antibodies. In this review, we discuss the immunotherapy approaches, especially monoclonal antibodies which are mostly used in cancer immunotherapy in clinical applications.

引用

页码：2935 / 2940

页数：6

共 45 条

[1] Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy [J].

Al-Sawaf, Othman ;

Fischer, Kirsten ;

Engelke, Anja ;

Pflug, Natali ;

Hallek, Michael ;

Goede, Valentin .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :295-304

[2]

Barbaros M.B., 2015, ERCIYES UNIV FEN BIL, V31, P177

[3]

Bean ES, 2000, METHODS ANTIBODY PRO, P31

[4] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells [J].

Boyerinas, Benjamin ;

Jochems, Caroline ;

Fantini, Massimo ;

Heery, Christopher R. ;

Gulley, James L. ;

Tsang, Kwong Yok ;

Schlom, Jeffrey .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) :1148-1157

[5]

Cai HH., 2017, MOJI, V6, P82, DOI [DOI 10.15406/MOJI.2017.05.00145, 10.15406/moji.2017.05.00145]

[6] Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - Impact of effector cells [J].

Chung, Shan ;

Lin, Yuwen L. ;

Reed, Chae ;

Ng, Carl ;

Cheng, Zhijie Jey ;

Malavasi, Fabio ;

Yang, Jihong ;

Quarmby, Valerie ;

Song, An .

JOURNAL OF IMMUNOLOGICAL METHODS, 2014, 407 :63-75

[7] Dinutuximab: First Global Approval [J].

Dhillon, Sohita .

DRUGS, 2015, 75 (08) :923-927

[8]

Dimberu Peniel M., 2011, Yale Journal of Biology and Medicine, V84, P371

[9] Cancer immunotherapy: the beginning of the end of cancer? [J].

Farkona, Sofia ;

Diamandis, Eleftherios P. ;

Blasutig, Ivan M. .

BMC MEDICINE, 2016, 14

[10]

Fuenmayor Jaheli, 2011, Cancers (Basel), V3, P3370, DOI 10.3390/cancers3033370

← 1 2 3 4 5 →